AAW donates $2.1m worth of breast cancer medication to KRCS

‘Our aim is to support tireless efforts of KRCS’

KUWAIT CITY, Jan 26: Ali Abdulwahab Al Mutawa Commercial Company (AAW) and Hoffmann-La Roche, the Swiss multinational healthcare company, announced today the donation of US$ 2.1 million worth of Herceptin, the curative breast cancer medication provided by Hoffmann-La Roche, to the Kuwait Red Crescent Society (KRCS). The initiative was announced during a meeting held on Sunday, January 24, at AAW headquarters, between AAW Chairman and CEO Mr. Faisal Ali Al Mutawa, KRCS Chairman Dr. Hilal Musaed Al-Sayer, and Hoffmann La Roche Country Manager at Gulf Countries Mr. Ahmed Tawfik.

The meeting was attended by KRCS Counselor of the Board of Directors, Director of Youth and Volunteering and Legal Department, Mr. Musaed Rashed Al-Enizi, AAW Pharmaceuticals General Manager, Dr. Sherif Younan, and representatives of Hoffmann-La Roche.

AAW Chairman and CEO, Mr. Faisal Ali Al Mutawa said: “Our aim with this donation is to support the tireless efforts of the Kuwaiti Red Crescent and their plight to protect atrisk breast cancer patients during the COVID-19 pandemic. This is our social responsibility to support at-risk patients in this precarious period with any challenges they may face, particularly their treatment expenses.”

Dr. Hilal Al-Sayer thanked Mr. Faisal Al Mutawa for his generous contribution and expressed his appreciation for AAW’s on-going commitment towards the society and the company’s efforts in supporting KRCS national and humanitarian programs.

Dr. Ahmed Tawfik extended his appreciation and gratitude to AAW and their social commitment to the State of Kuwait and praised the role of the Kuwaiti Red Crescent in supporting charities both locally and regionally. Dr Tawfik further reiterated that the needs of patients and the healthcare system is a vital part of La Roche’s company ethos.